Real-world Clinical Patterns Of Care And Outcomes Among Patients In Africa Middle East (Afme) With Metastatic Renal Cell Carcinoma (Mrcc) Receiving Sunitinib As First Line Therapy. Prospective Primary Data Collection Study
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OPTIMISE
- Sponsors Pfizer
- 26 Sep 2017 Status changed from not yet recruiting to recruiting.
- 12 Jun 2017 Planned initiation date changed from 24 May 2017 to 30 Jun 2017.
- 08 May 2017 New trial record